학술논문
From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function.
Document Type
Academic Journal
Author
Medina-Julio D; Department of Internal Medicine, General Hospital 'Dr. Manuel Gea González', Mexico City, Mexico.; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Ramírez-Mejía MM; Liver Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.; Plan of Combined Studies in Medicine (PECEM-MD/PhD), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Cordova-Gallardo J; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Department of Hepatology, Service of Surgery and Obesity Clinic, General Hospital 'Dr. Manuel Gea González', Mexico City, Mexico.; Peniche-Luna E; High Academic Performance Program (PAEA), Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Cantú-Brito C; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Departament of Neurology, National Institute of Medical Sciences and Nutrition 'Salvador Zubirán', Mexico City, Mexico.; Mendez-Sanchez N; Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.; Liver Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico.
Source
Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 9609063 Publication Model: Electronic Cited Medium: Internet ISSN: 1643-3750 (Electronic) Linking ISSN: 12341010 NLM ISO Abbreviation: Med Sci Monit Subsets: MEDLINE
Subject
Language
English
Abstract
Metabolic dysfunction-associated fatty liver disease or metabolic dysfunction-associated steatotic liver disease (MAFLD/MASLD), is a common chronic liver condition affecting a substantial global population. Beyond its primary impact on liver function, MAFLD/MASLD is associated with a myriad of extrahepatic manifestations, including cognitive impairment. The scope of cognitive impairment within the realm of MAFLD/MASLD is a matter of escalating concern. Positioned as an intermediate stage between the normal aging process and the onset of dementia, cognitive impairment manifests as a substantial challenge associated with this liver condition. Insights from studies underscore the presence of compromised executive function and a global decline in cognitive capabilities among individuals identified as being at risk of progressing to liver fibrosis. Importantly, this cognitive impairment transcends mere association with metabolic factors, delving deep into the intricate pathophysiology characterizing MAFLD/MASLD. The multifaceted nature of cognitive impairment in the context of MAFLD/MASLD is underlined by a spectrum of factors, prominently featuring insulin resistance, lipotoxicity, and systemic inflammation as pivotal contributors. These factors interplay within the intricate landscape of MAFLD/MASLD, fostering a nuanced understanding of the links between hepatic health and cognitive function. By synthesizing the available evidence, exploring potential mechanisms, and assessing clinical implications, the overarching aim of this review is to contribute to a more complete understanding of the impact of MAFLD/MASLD on cognitive function.